@article {Roca2020.12.10.20238576, author = {Anna Roca and MRCG/GG COVID-19 working group}, editor = {Bojang, Abdoulie and Sesay, Abdul Karim and Vilane, Aminata and Prentice, Andrew and Roca, Anna and Jaye, Assan and Awokola, Babatunde and Abatan, Baderinwa and Kampmann, Beate and Nadjm, Behzad and Susso, Bubacarr and Cerami, Carla and Nwakanma, Davis and Clarke, Ed and Usuf, Effua and Okoh, Emmanuel and Oriero, Eniyou and Nkereuwem, Esin and Akemoke, Fatai and Oko, Francis and Jah, Hawanatu and Brotherton, Helen and Bojang, Kalifa and Forrest, Karen and Hofmann, Natalie and Mohammed, Nuredin and Ndiath, Mamadou Ousmane and Antonio, Martin and Martinez-Alvarez, Melisa and Jobe, Modou and Agboghoroma, Orighomisan and Secka, Ousman and Jarju, Sheikh and de Silva, Thushan and Okomo, Uduak and D{\textquoteright}Alessandro, Umberto and Oghenebrume, Wariri and Olatunji, Yekini and Samateh, Ahmadou and Sabally, Babanding and Manjang, Buba and Roberts, Charles and Drammeh, Mariama and Bittaye, Mustapha and Sambou, Sana and Jagne, Sherifo and Singhateh, Yankuba}, title = {Intense and Mild Wave of COVID-19 in The Gambia: a Cohort Analysis}, elocation-id = {2020.12.10.20238576}, year = {2020}, doi = {10.1101/2020.12.10.20238576}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background The SARS-CoV-2 pandemic is evolving differently in Africa compared to other regions, with lower transmission and milder clinical presentation. Reasons for this are not fully understood. Recent data from Eastern and Southern Africa suggest that transmission may be higher than measured. Detailed epidemiological data in different African settings is urgently needed.Methods We calculated cumulative rates of SAR-CoV-2 infections per 1,000 people at risk in The Gambia (2.42 million individuals) using publicly available data. We evaluated these rates in a cohort of 1,366 employees working at the MRC Unit The Gambia @LSHTM (MRCG) where systematic surveillance of symptomatic cases and contact tracing was implemented. Cumulative rates among the Gambian population were stratified by age groups and, among MRCG staff, by occupational exposure risk. SARS-CoV-2 testing was conducted on oropharyngeal/nasopharyngeal samples with consistent sampling and laboratory procedures across cohorts.Findings By September 2020, 3,579 cases of SARS-CoV-2 and 115 deaths had been identified; with 67\% of cases detected in August. Among them, 191 cases were MRCG staff; all of them were asymptomatic/mild, with no deaths. The cumulative incidence rate for SARS-CoV-2 infection among MRCG staff (excluding those with occupational exposure risk) was 129 per 1,000, at least 20-fold higher than the estimations based on diagnosed cases in the adult Gambian population.Interpretation Our findings are consistent with recent African sero-prevalence studies reporting high community transmission of SAR-CoV-2. Enhanced community surveillance is essential to further understand and predict the future trajectory of the pandemic in Africa.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSource of funding for the infection control activities and COVID-19 testing at the MRCG are UKRI covid response MC_PC 19061 and European Union COVID-19 response FED/2020/417-470. The funders have no role in the data analysis, design or interpretation. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Gambia Government / MRCG Joint Ethics Committee approved the data analysis and manuscript submission (Submission ID/Ethics Ref: 2020.E37).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe MRC Unit The Gambia at the LSHTM has a governance department were all enquiries regarding access to data need to be submitted.}, URL = {https://www.medrxiv.org/content/early/2020/12/11/2020.12.10.20238576}, eprint = {https://www.medrxiv.org/content/early/2020/12/11/2020.12.10.20238576.full.pdf}, journal = {medRxiv} }